rProtein A/Protein G GraviTrap includes ten ready-to-use columns prepacked with 1 ml of a mixture of 50% rProtein A Sepharose Fast Flow and 50% Protein G Sepharose 4 Fast Flow.
rProtein A/Protein G GraviTrap includes ten ready-to-use columns prepacked with 1 ml of a mixture of 50% rProtein A Sepharose Fast Flow and 50% Protein G Sepharose 4 Fast Flow.
•Prepacked gravity-flow columns provide convenience, save time, and increase the reliability of your results.
•Purification of antibodies in 30 min allows you to quickly obtain and store your target protein in order to avoid the inherent dangers of protein instability and degradation associated with slow and long purification runs.
•High purity and recovery with purity > 95% in one step and recovery typically 70% to 80%.
•High binding capacity such as Protein A/Protein G GraviTrap ~ 35 mg human IgG/column.
rProtein A/Protein G GraviTrap are prepacked gravity-flow columns designed for fast and efficient manual purification of monoclonal and polyclonal antibodies, antibody fragments from cell culture supernatant, and biological fluids. The antibodies are simply captured with high specificity on protein A and protein G ligands in gravity-flow columns. You do not need any other instrument with this protocol because the entire process relies on the flow of gravity. The yield varies from 20 to 50 mg of purified antibodies depending on the ligand you use. The columns are reusable up to five times.
Sartorius Stedim Biotech develops next generation of its successful single-use laboratory bioreactor.
Proven glass bioreactor design with the efficiency and flexibility of single-use systems
New single-use sensors for non-invasive measurement of the pH and dissolved oxygen
Connection Boxes for BIOSTAT® controllers and other brands of bioreactor controller
Sartorius Stedim Biotech (SSB), a leading international equipment provider for the biopharmaceutical industry, presents UniVessel® SU, the second generation of its successful single-use bioreactor. This single-use stirred tank bioreactor can be operated in a choice of working volumes ranging from 0.6L to 2L, and is suitable for the cultivation of mammalian cells, including stem cells, insect and plant cells. Typical areas of application for the UniVessel® SU are process development and optimization, as well as production of seed cultures and cell banks.
Fast and flexible for efficient management of peak workloads despite challenging timelines UniVessel® SU combines the proven design of conventional glass vessels with the efficiency and flexibility of single-use systems. Supplied as a completely preassembled and presterilized unit, this laboratory bioreactor is instantly ready to use right out of the box. It eliminates the need for labor-intensive steps, such as autoclaving or installation of probes, minimizing the time needed for preparation. The new UniVessel® SU can be used interchangeably with glass vessels to help laboratories better manage peak workloads despite challenging timelines.
Single-use sensors for non-invasive measurement of pH and dissolved oxygen Each UniVessel® SU is equipped with integrated single-use sensors for pH and dissolved oxygen measurement. This proven single-use sensor technology, which SSB also uses in its BIOSTAT® RM and BIOSTAT® STR disposable bioreactors, measures the pH and DO values non-invasively, thus eliminating time-consuming autoclaving and risk-prone insertion of probes in the culture vessel.
Connection Boxes interface UniVessel® SU with existing bioreactor controllers UniVessel® SU is compatible with SSB BIOSTAT® controllers and can also be operated with nearly any other brand of bioreactor controller. This saves customers from having to buy expensive new equipment. The new UniVessel® SU Connection Box enables the integrated single-use sensors of UniVessel® SU to be used with existing controllers. Up to four bioreactor controllers can be interfaced per Connection Box. The sensor calibration data can be read in easily by a barcode scanner in an error-free manner.
Thermo Fisher Scientific releases new small benchtop centrifuge, which provides scientists with outstanding capacity in a compact design.
Thermo Fisher Scientific Inc. has launched a new small benchtop centrifuge to meet clinical and research needs alike.
“Centrifuges are in constant use and demand so preventing downtime and bottlenecks is crucial,” said Maurizio Merli, product director, Thermo Fisher Scientific. “With features designed for simplicity, safety and flexibility, the new small benchtop centrifuges can help scientists save time and maximize resources.”
The new centrifuges provide:
Application flexibility, convenient cleaning and ease-of-use with Thermo ScientificAuto-Lock rotor exchange
Versatility to spin blood tubes, conical tubes, microtubes and microplate compatibility with sealing options
One-handed sample protection with Thermo Scientific ClickSeal biocontainment lids, certified by the Public Health Laboratory Service in Porton Down
Intuitive glove and detergent-friendly interface with a bright display, one-touch operation with pre-set protocol options and optional password protection
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.
Designed by R-Tech Ueno, RU-101 ophthalmic solution is being trialled as a therapy for severe dry eye, for which no effective treatment is currently available. The recombinant human albumin is part of Novozymes Biopharma’s albumin range. Novozymes Biopharma has a strong reputation in the industry for helping customers in the safe and successful commercialization and approval of new products.
The prevalence of severe dry eye, where patients suffer from instability of the tear film, continues to increase. It is the most diagnosed of all ophthalmic disorders and estimates put the market at approximately 1.5 billion USD. The trials for RU-101 ophthalmic solution will move ahead in two stages, the first of which will assess safety using a placebo control, and allow confirmation of the maximum dose. The second stage will then use this maximum dose for 12 weeks to evaluate the safety and effectiveness of RU-101 ophthalmic solution.
Dermot Pearson, Marketing Director at Novozymes Biopharma said, “Novozymes is dedicated to supporting our customers in the drug development and testing stages, and in assisting with the optimisation of their pathways through regulatory approval procedures. We are therefore delighted that RU-101 ophthalmic solution has been approved for clinical testing.”
Novozymes Biopharma’s recombinant albumin is designed to provide quality performance benefits when included in drugs developed by our customers. It was selected as a key component of this novel therapy back in 2011, due to its proven high quality and enhanced safety profile. Animal-free, with an exceptional purity profile and convenient liquid format at room temperature, recombinant albumin delivers consistent levels of quality, leading to reduced lot testing and vendor auditing.
All Novozymes’ recombinant human albumins deliver stable, safe and regulatory compliant ingredients for drug delivery and formulation, and are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP).
the Wyss Institute for Biologically Inspired Engineering at Harvard University and Sony DADC announced a collaboration that will harness Sony DADC’s global manufacturing expertise to further advance the Institute’s Organs-on-Chips technologies.
Human Organs-on-Chips are composed of a clear, flexible polymer about the size of a computer memory stick, and contain hollow microfluidic channels lined by living human cells – allowing researchers to recapitulate the physiological and mechanical functions of the organs, and to observe what happens in real time. The goal is to provide more predictive and useful measures of the efficacy and safety of new drugs in humans – and at a fraction of the time and costs associated with traditional animal testing.
“We are excited to apply Sony DADC’s deep manufacturing expertise to confront one of the major challenges in the life sciences by helping to accelerate the translation of the Wyss Institute’s Organ-on-Chips from the benchtop to the marketplace,” said Christoph Mauracher, Senior Vice President of the BioSciences division of Sony DADC. “The Organs-on-Chips have the potential to revolutionize testing of drugs, chemicals, toxins and cosmetics.”
This collaboration builds on the momentum the Wyss Institute team has gained recently on its Organs-on-Chips research program. With support from Defense Advanced Research Projects Agency (DARPA)*, National Institutes of Health (NIH), Food and Drug Administration (FDA), and pharmaceutical partners, more than ten Organs-on-Chips are currently under development at the Wyss Institute, including a lung, heart, liver, kidney, bone marrow, and gut-on-a-chip; there is also a major effort to integrate these organ chips into “human body on-chips” that mimic whole body physiology.
In February, Wyss Founding Director Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program, received the prestigious 3Rs Prize from the UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research for the lung-on-a-chip. This month, the Society of Toxicology awarded him the Leading Edge in Basic Science Award for his “seminal scientific contributions and advances to understanding fundamental mechanisms of toxicity.”
“Our work with Sony DADC is a wonderful example of the Wyss Institute model in action,” said Ingber. “We collaborate with industry to help de-risk the technologies we develop, both technically and commercially, and therefore expedite their translation into real world applications.”
*Part of this research was sponsored by the U.S. Army Research Office (ARO) and DARPA; the views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of ARO, DARPA or the U.S. Government.
Wyss Institute for Biologically Inspired Engineering
The PA 800 plus next-generation CE-platform from Beckman Coulter Life Sciences provides automated, quantitative analysis of protein purity, charge isoform distribution and glycan structure.
Beckman Coulter Life Sciences have products offering a range of biotech, analytical chemistry and industrial applications at the Pittcon Conference and Expo, March 18-21, in Philadelphia, USA.
One example of new applications is found with the PA 800 plus next-generation capillary electrophoresis (CE) platform, which provides automated, quantitative analysis of protein purity, charge isoform distribution and glycan structure. Originally designed with biopharmaceutical analysis in mind, the system can also be used in food and beverage quality studies for monosaccharide and protein analysis, and in the quantitative characterization of ions, organic acids and other charged or polar molecules of importance.
Beckman Coulter, Inc., based in California, USA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories on six continents. For more than 75 years, Beckman Coulter products have been making a difference in peoples’ lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and reducing the cost of care. For more information, visit www.beckmancoulter.com.
Hillary Hunter, Beckman Coulter Life Sciences Public Relations
Sartorius Stedim Biotech, a leading international supplier for the pharma and biotech industries, has launched new sizes XS and S of the Clipster® Aseptic Disconnector, in addition to the existing size L.
Clipster® Aseptic Disconnector makes aseptic tubing disconnection easy.
The Clipster® Aseptic Disconnector XS (yellow), S (red) and L (white) is used after a fluid transfer to disconnect single-use transfer lines and bag assemblies made of silicone or TPE tubes.
This single-use device allows an aseptic disconnection of Silicone (Pt) as well as thermoplastic elastomer (TPE) tubes in biopharmaceutical manufacturing processes. It is safe, quick, easy to use and available as a standalone product or pre-mounted on single-use transfer lines and bag assemblies. The Clipster® Aseptic Disconnector is used after a fluid transfer to disconnect transfer lines and bag assemblies. The disconnection of tubes can be performed in non-classified and classified environments while maintaining product sterility. It is performed with a hand-held tool which ensures easy execution in various space requirements. The Clipster® Aseptic Disconnector XS, S or L can be applied to multiple tubing material (silicone and TPE) and sizes from 1/8”x1/4” up to 1/2” x 3/4”.
The validation of this key single-use device has been carried out under the most stringent test regimes. Biological and physical tests have been combined to provide data representing a variety of process conditions including critical applications.
Lipocalyx, the provider of the latest transfection technology starts marketing and sales in Great Britain as of today.
The offering will feature the reagents Viromer®Blue and Viromer®Green, critical materials for the work with RNAi. Christian Reinsch, PI at Lipocalyx says: “We knew it is good stuff - but still, it was quite rewarding for us to see Viromers working in other people’s hands. The labs out there used it in challenging experiments and the reality check went really well”.
For the marketing in the UK, Lipocalyx has partnered with Voicentric, a communicator specialized in the life science sector. Steffen Panzner, CEO of Lipocalyx comments: “Expanding the marketing outside Germany was the thing to do and with Voicentric we found a like-minded partner. When we reach out to the scientist, listening and developing solutions is of the same importance to us as presenting the Viromer story. In that regard, we didn’t need to explain much to Voicentric”.
Lipocalyx GmbH, a drug delivery company based in Halle/Saale, Germany started its venture in August 2011 to create entirely novel polymer-based transfectants for oligonucleotides. The team has a strong background in siRNA transfection and chemistry. Lipocalyx received seed financing by IBG RKF II, managed by Goodvent in Magdeburg and High-Tech Gründerfonds (HTGF) in Bonn.
Voicentric Ltd is a marketing agency which specialises in Life-Science and similarly high-tech and research based disciplines. People at Voicentric communicate complex messages - predominantly by telephone - about products and services which improve and facilitate thier research. The company has formed strong ties with the University of Durham.
Miniature component specialists LEE PRODUCTS have recently published a new EFS (Electro Fluidic Systems) technical handbook which provides a valuable resource of product information along with practical engineering reference material.
Lee Product’s three Electro-Fluidic Systems groups produce high quality miniature solenoid valves, micro-dispense valves, atomising and dispense nozzles, fixed and variable volume pumps, integrated fluidic manifolds, inert tubing and fluid control components and custom engineered designs. These products are used in medical and scientific instrumentation, analytical / clinical chemistry, in-vitro diagnostics, drug discovery and ink jet printing applications.
This new 323 page EFS handbook includes detailed information on Lee’s wide range of solenoid valves and pumps along with their manifolds, tubing, accessories, and special products, plus useful engineering and general information.
More details and copies of the handbook are available from:
Automated RNA Sequencing Service from Beckman Coulter Genomics
Provides Fast, High Quality Results.
HiSeq* and Biomek platforms support a complete RNA-Seq solution
High throughput end-to-end RNA-Seq Service from Beckman Coulter Genomics includes customized project design, automated Illumina* TruSeq* RNA-Seq library construction and flexible, multiplexed sequencing on the Illumina HiSeq platform. Downstream bioinformatics analysis options include primary data analysis, differential gene expression, splice variant analysis, gene fusion identiﬁcation and rare transcript identiﬁcation.
The new automated library construction process uses Illumina TruSeq RNA sample preparation kits in conjunction with Beckman Coulter Life Sciences’ Biomek* liquid handling platforms. Libraries show consistent size distribution and sequencing data is reproducible, showing good correlation with the published industry standard.
Total RNA from multiple species – including mammalian, plant and yeast samples – has been validated using the automated process. The scalable, high throughput service allows processing from one to hundreds of samples without compromising quality.
“Automated processing of RNA-Seq using the Biomek platform provides high quality data, and accommodates projects from small to large,” said Bernhard Spiess, vice president of sales and marketing, Beckman Coulter Genomics. “We are very pleased with this enhanced service and the ability to provide scientists with reliable, reproducible results in a timely manner.”
Technical experts in the company’s genomics services group utilize extensive experience to provide highly reliable data. Typical turnaround time is four to seven weeks after sample receipt. For more information about this service, please visit www.beckmangenomics.com/rna-seq
* All trademarks are property of their respective owners.
Beckman Coulter, the stylized logo and Biomek are registered trademarks of Beckman Coulter, Inc.
PromoFectin facilitates the highly efficient and reproducible delivery of nucleic acids into a variety of cell types, including many hard-to-transfect cell lines and primary cells.
It is a stable non-liposomal polymer, that is water-soluble and free of any components of animal origin. PromoFectin shows very low toxicity and is therefore ideally suited for the transfection of sensitive cells, yielding optimal transfection efficiencies and gene expression. Transfection with PromoFectin requires no medium change and it can be used for adherent and non-adherent cells. It compacts and protects the nucleic acid of interest, enables efficient transport into cells via endocytosis and allows for a rapid and almost complete release of the intact nucleic acid into the cytosol – all of which favor delivery to the nucleus.
Special cell type specific PromoFectin variants are also available, which were developed for the efficient but gentle transfection of cells such as endothelial cells (e.g. primary HUVECs), hepatocytes, macrophages, or neuronal cells.
PromoKine also offers ready-to-use kits for fast and convenient detection and quantification of reporter gene expression including the commonly used reporter proteins luciferase (Firefly & Renilla), beta-galactosidase (reporter assay & staining kits) and GFP. The kits are highly sensitive, easy to handle and yield reproducible results. Substrates for the luciferase and beta-galactosidase assays are also available separately.
In addition, PromoKine provides a range of small-sized reporter plasmids (beta-galactosidase, luciferase, GFP, CAT, SEAP) as well as fusion plasmids, which allow high-level expression of a target gene of interest with a GFP or luciferase fusion tag at its C- or N-terminus.
7th Berlin Conference on IP in Life Sciences: Big Data, Big Drugs
The health care industry faces significant transformation, driven by a boom in knowledge within biomedical sciences and breakthrough technologies such as gene sequencing. The management of "big data“ will change the understanding of diseases, development of drugs and treatment of patients. more